These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2021-003524-32 Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE) Terapia neoadiuvante con pembrolizumab nei tumori della tiroide ad alto rischio not-yet-due